| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ad53b64eb74859acdc01278829b080
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c524154a4a70b1f9ea0b869419b9475d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2814
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5421
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-515 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-714 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9d4cf136cd7f236104f16eea80edc86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f6aa27540cc3ec6726575a28537d8ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_937f7ce7b4e350ff3f315454a64369b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a5bf7830f02998225666b701e9d6051 |
| publicationDate |
2018-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018001844-A1 |
| titleOfInvention |
Biomarkers of blood-brain barrier dysfunction |
| abstract |
A method for determining whether a subject has an impaired blood-brain barrier (BBB) or is at risk of developing an impaired blood-brain barrier (BBB) comprising determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the one or more biomarkers comprise serum amyloid A (SAA). |
| priorityDate |
2016-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |